<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39369333</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-4243</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Infectious diseases (London, England)</Title><ISOAbbreviation>Infect Dis (Lond)</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of remdesivir in patients with COVID-19 and severe renal insufficiency: a nationwide cohort study in Japan.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/23744235.2024.2409729</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The effectiveness of remdesivir in patients with coronavirus disease 2019 (COVID-19) and severe renal insufficiency remains underexplored.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To evaluate whether remdesivir reduces the risk of mortality or invasive mechanical ventilation/extracorporeal membrane oxygenation (IMV/ECMO) in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective observational study utilising the COVID-19 Registry Japan (COVIREGI-JP) included noncritical patients with COVID-19 and severe renal insufficiency (defined as serum creatinine levels ≥3 mg/dL, on maintenance dialysis, or kidney transplant recipients) admitted to Japanese hospitals within 7 days of symptom onset between January 1, 2020 and May 8, 2023. Patients were classified into the remdesivir group if remdesivir was initiated within the first 2 days of admission. We estimated the multivariable-adjusted hazard ratio (HR) for mortality and initiation of IMV/ECMO using landmark analysis to address immortal time bias.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 1,449 patients included in the landmark analysis (median age, 74 years [interquartile range 62-84 years]; 992 [68.5%] were male), 272 initiated remdesivir within the first 2 days of admission. During the 28 days from the landmark timepoint, 19 (7.0%) and 136 (11.6%) patients in the remdesivir and control groups, respectively, had an outcome. The remdesivir group had a lower risk of mortality or IMV/ECMO initiation than the control group (adjusted HR, 0.44; 95% confidence interval, 0.23-0.83).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In noncritical patients with COVID-19 and severe renal insufficiency at admission, initiating remdesivir early after disease onset, within the first 2 days of admission, led to a lower risk of mortality or IMV/ECMO initiation, compared with non-initiation of remdesivir.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itaya</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayakawa</LastName><ForeName>Kayoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis (Lond)</MedlineTA><NlmUniqueID>101650235</NlmUniqueID><ISSNLinking>2374-4243</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">renal insufficiency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>8</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39369333</ArticleId><ArticleId IdType="doi">10.1080/23744235.2024.2409729</ArticleId></ArticleIdList></PubmedData></PubmedArticle>